Exenatide ER (Bydureon BCise)

Exenatide extended-release (Bydureon BCise) holds the distinction of being the world's first once-weekly GLP-1 receptor agonist approved for clinical use, and it was this dosing convenience innovation — not exenatide twice-daily (Byetta) — that set the template for the entire once-weekly GLP-1 landscape that followed. AstraZeneca developed Bydureon BCise as an easy-to-use, single-dose auto-injector tray that delivers 2mg of exenatide weekly without needle assembly, improving on the original Bydureon powder reconstitution that many patients found cumbersome. As a GLP-1 receptor agonist, exenatide ER reduces HbA1c through glucose-dependent insulin stimulation, suppresses inappropriate glucagon secretion, and reduces appetite — but its weight loss outcomes in clinical trials have consistently been the weakest among once-weekly GLP-1 agents, at approximately 2 to 3 kg versus placebo. The EXSCEL cardiovascular outcomes trial (n=14,752) demonstrated non-inferiority for cardiovascular safety (HR 0.91, 95% CI 0.83-1.00) but did not demonstrate superiority, unlike semaglutide's SELECT trial. Nausea is reported in 31.7 percent of patients — the highest nausea rate in the class — and injection-site nodule formation is a distinctive adverse effect specific to the PLGA microsphere formulation. The Bydureon BCise auto-injector requires weekly shaking to resuspend the microspheres and cannot be frozen, adding handling complexity. In 2026, exenatide ER is primarily prescribed for patients with type 2 diabetes who are already stabilized on it, where switching costs (both financial and clinical) outweigh the incremental benefits of newer agents. New prescriptions for exenatide ER for weight management are rare given the dramatically superior alternatives now available. Despite these limitations, it remains in current prescribing for established T2D patients where continuity of care outweighs switching to a newer agent.